Nexium Ruling Offers Road Map For Pay-For-Delay Classes

Law360, New York (January 23, 2015, 7:51 PM EST) -- The First Circuit's decision to uphold class certification in the Nexium pay-for-delay litigation despite the presence of some uninjured members in the group may be a hollow victory for the heartburn-drug purchasers after their recent loss at trial, but the ruling offers a boost for other plaintiffs as a bevy of antitrust class actions over pharmaceutical patent settlements forge ahead.

A split three-judge panel ruled Wednesday that the Massachusetts district court hadn't abused its discretion in certifying a class of consumers, insurers and other entities who...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.